Lantern Pharma (NASDAQ:LTRN) Issues Earnings Results, Beats Expectations By $0.07 EPS

Lantern Pharma (NASDAQ:LTRN) released its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.07, RTT News reports. During the same quarter in the previous year, the firm earned ($0.51) earnings per share.

Lantern Pharma Trading Down 4.9%

LTRN opened at $3.86 on Friday. The company has a market capitalization of $41.63 million, a price-to-earnings ratio of -2.17 and a beta of 1.63. Lantern Pharma has a 12-month low of $2.55 and a 12-month high of $6.80. The business’s fifty day simple moving average is $3.55 and its 200-day simple moving average is $3.73.

Analyst Ratings Changes

Separately, Lake Street Capital assumed coverage on Lantern Pharma in a report on Wednesday, April 2nd. They issued a “buy” rating and a $25.00 price target for the company.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.